Cyclacel Pharmaceuticals, Inc. (CYCC) Stock

About Cyclacel Pharmaceuticals, Inc.

Cyclacel Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development stage, focused on discovering and advancing treatments for various cancers and other diseases involving abnormal cell growth. The company's active drug pipeline includes several promising candidates: Fadraciclib, a cyclin-dependent kinase (CDK) inhibitor, is presently undergoing Phase 1/2 clinical studies for solid tumors and is also being evaluated in combination with venetoclax for patients with chronic lymphocytic leukemia that has recurred or is resistant to previous therapies. CYC140, a polo-like kinase inhibitor, has progressed to Phase 1/2 clinical trials for the treatment of both advanced leukemias and solid malignancies. Sapacitabine, an innovative orally available nucleoside analog (a prodrug of CNDAC), is also in Phase 1/2 clinical trials, targeting acute myeloid leukemia and myelodysplastic syndrome. The pipeline further features Seliciclib, another CDK inhibitor, which is being investigated in investigator-sponsored trials (ISTs), including a Phase 2 study for Cushing's disease and a Phase 1/2 study for advanced rheumatoid arthritis. In a key strategic alliance, Cyclacel has collaborated with the University of Texas MD Anderson Cancer Center. This partnership aims to clinically assess the safety and therapeutic potential of three of Cyclacel's compounds in patients with a range of blood cancers, such as chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other forms of advanced leukemia. The company's main operational base is situated in Berkeley Heights, New Jersey.

Cyclacel Pharmaceuticals, Inc. is headquartered in US.

Cyclacel Pharmaceuticals, Inc. (CYCC) stock trades at $6.37 with a market capitalization of $10.61M. The stock is valued at a price-to-earnings (P/E) ratio of -26.54, price-to-book of 5.14, price-to-sales of 6.96. Over the past 52 weeks the stock has ranged between $3.08 and $597.60, and currently trades 98.9% below its 52-week high.

On profitability, Cyclacel Pharmaceuticals, Inc. generates a return on equity (ROE) of -72.25%, return on capital employed of -53.74%, an operating margin of -238.49%, a net profit margin of -204.20%.

Official website: www.cyclacel.com